学术探索
学术期刊
新闻热点
数据分析
智能评审

Brief report - The HBV drug entecavir - Effects on HIV-1 replication and resistance

被引：173
作者：
McMahon, Moira A.
Jilek, Benjamin L.
Brennan, Timothy P.
Shen, Lin
Zhou, Yan
Wind-Rotolo, Megan
Xing, Sifei
Bhat, Shridhar
Hale, Braden
Hegarty, Robert
Chong, Curtis R.
Liu, Jun O.
Siliciano, Robert F.
Thio, Chloe L.
机构：
[1] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21231 USA
[2] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA
[3] Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA
[4] Natl Naval Med Ctr, Div Infect Dis, San Diego, CA USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2007年 / 356卷 / 25期
关键词：
D O I：
10.1056/NEJMoa067710
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Entecavir, a drug approved by the Food and Drug Administration for the treatment of chronic hepatitis B virus (HBV) infection, is not believed to inhibit replication of human immunodeficiency virus type 1 (HIV-1) at clinically relevant doses. We observed that entecavir led to a consistent 1-log(10) decrease in HIV-1 RNA in three persons with HIV-1 HBV coinfection, and we obtained supportive in vitro evidence that entecavir is a potent partial inhibitor of HIV-1 replication. Detailed analysis showed that in one of these patients, entecavir monotherapy led to an accumulation of HIV-1 variants with the lamivudine-resistant mutation, M184V. In vitro experiments showed that M184V confers resistance to entecavir. Until more is known about HIV-1-resistance patterns and their selection by entecavir, caution is needed with the use of entecavir in persons with HIV-1 and HBV coinfection who are not receiving fully suppressive antiretroviral regimens.
引用
收藏
页码：2614 / 2621
页数：8
相关论文
共 30 条
[1]   Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme [J].
Back, NKT ;
Nijhuis, M ;
Keulen, W ;
Boucher, CAB ;
Essink, BBO ;
vanKuilenburg, ABP ;
vanGennip, AH ;
Berkhout, B .
EMBO JOURNAL, 1996, 15 (15) :4040-4049
[2]   Residual human immunodeficiency virus type 1 viremia in some patients on Antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells [J].
Bailey, JR ;
Sedaghat, AR ;
Kieffer, T ;
Brennan, T ;
Lee, PK ;
Wind-Rotolo, M ;
Haggerty, CM ;
Kamireddi, AR ;
Liu, Y ;
Lee, J ;
Persaud, D ;
Gallant, JE ;
Cofrancesco, J ;
Quinn, TC ;
Wilke, CO ;
Ray, SC ;
Siliciano, JD ;
Nettles, RE ;
Siliciano, RF .
JOURNAL OF VIROLOGY, 2006, 80 (13) :6441-6457
[3]  
Bartholomeusz A, 2004, ANTIVIR THER, V9, P149
[4]   The M184V mutation reduces the selective excision of zidovudine 5′-monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1 [J].
Boyer, PL ;
Sarafianos, SG ;
Arnold, E ;
Hughes, SH .
JOURNAL OF VIROLOGY, 2002, 76 (07) :3248-3256
[5]  
*DEP HLTH HUM SERV, 2006, GUID US ANT AG HIV 1
[6]   INHIBITION OF THE REPLICATION OF HEPATITIS-B VIRUS INVITRO BY 2',3'-DIDEOXY-3'-THIACYTIDINE AND RELATED ANALOGS [J].
DOONG, SL ;
TSAI, CH ;
SCHINAZI, RF ;
LIOTTA, DC ;
CHENG, YC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (19) :8495-8499
[7]  
Gallant JE, 2003, ANTIVIR THER, V8, P489
[8]   THE SAME MUTATION THAT ENCODES LOW-LEVEL HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 RESISTANCE TO 2',3'-DIDEOXYINOSINE AND 2',3'-DIDEOXYCYTIDINE CONFERS HIGH-LEVEL RESISTANCE TO THE (-) ENANTIOMER OF 2',3'-DIDEOXY-3'-THIACYTIDINE [J].
GAO, Q ;
GU, ZX ;
PARNIAK, MA ;
CAMERON, J ;
CAMMACK, N ;
BOUCHER, C ;
WAINBERG, MA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (06) :1390-1392
[9]   INHIBITORY EFFECT OF 9-(2-PHOSPHONYLMETHOXYETHYL)-ADENINE (PMEA) ON HUMAN AND DUCK HEPATITIS-B VIRUS-INFECTION [J].
HEIJTINK, RA ;
DEWILDE, GA ;
KRUINING, J ;
BERK, L ;
BALZARINI, J ;
DECLERCQ, E ;
HOLY, A ;
SCHALM, SW .
ANTIVIRAL RESEARCH, 1993, 21 (02) :141-153
[10]   Identification of EMS-200475 as a potent and selective inhibitor of hepatitis B virus [J].
Innaimo, SF ;
Seifer, M ;
Bisacchi, GS ;
Strandring, DN ;
Zahler, R ;
Colonno, RJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (07) :1444-1448
123